Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients

NACompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Cellulitis
Interventions
DRUG

trimethoprim-sulfamethoxazole

"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~\> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"

DRUG

Cephalexin

"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~\> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Children's Hospital Boston, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT00676130 - Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients | Biotech Hunter | Biotech Hunter